Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice

Fig. 2

Effects of 5 weeks of cyclophosphamide (CY) and zoledronate (ZA) combination therapy on long bones. a Representative H-E-stained images (bar, 400 μm). Bone area per tissue area (BA/TA) was significantly increased in CY/ZA vs. vehicle control (VC) (**p < 0.01). b Representative TRAP-stained images (black arrowheads: osteoclasts on bone surface, BM: bone marrow, bar: 100 μm). The number of osteoclasts was significantly decreased in CY/ZA vs. VC (**p < 0.01). c Representative microCT images. Bone volume fraction (BVF) was significantly increased in CY/ZA vs. VC (***p < 0.001). Trabecular number (Tb.N) was the same in CY/ZA vs. VC, while trabecular thickness (Tb.Th) was significantly increased in CY/ZA vs. VC (***p < 0.001). Trabecular separation (Tb.Sp) was significantly decreased in CY/ZA vs. VC (*p < 0.05). Bone mineral density (BMD) was significantly increased in CY/ZA vs. VC (***p < 0.001). The Mann-Whitney U test was conducted to assess the non-parametric BA/TA data. Student’s t test was performed for all other analyzed parameters. n = 7/group

Back to article page